



31 9. Innovation Center for Advanced Medical Imaging and Intelligent Medicine, Guangzhou  
32 Institute of Technology, Xidian University, Guangzhou, Guangdong 51055, China.

33

34 **\*Corresponding author**

35 **Di Dong, PhD**

36 The CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of  
37 Sciences, No. 95 Zhongguancun East Road, Hai Dian District, Beijing, 100190, China.

38 **Tel:** +86 10 82618465

39 **Fax:** +86 10 62527995

40 **Email:** Di.Dong@ia.ac.cn

41

42 **Hui-mao Zhang, PhD**

43 Department of Radiology, The First Hospital of Jilin University, Changchun, 130021, China.

44 **Tel:** +86 0431 85166420

45 **Email:** huimao@jlu.edu.cn

46

47 **Jie Tian, PhD**

48 FAIMBE, FIAMBE, FIEEE, FSPIE, FOSA, FIAPR, FISMRM

49 The CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of  
50 Sciences, No. 95 Zhongguancun East Road, Hai Dian District, Beijing, 100190, China.

51 **Tel:** +86 10 82618465

52 **Fax:** +86 10 62527995

53 **Email:** jie.tian@ia.ac.cn

54

55 **Running Head:** The first signal-to-knowledge study based on human data

56

## 57 **Abstract**

58 Recently, image-based diagnostic technology has made encouraging and astonishing development.  
59 Modern medical care and imaging technology are increasingly inseparable. However, the current  
60 diagnosis pattern of Signal-to-Image-to-Knowledge inevitably leads to information distortion and  
61 noise introduction in the procedure of image reconstruction (Signal-to-Image). Artificial  
62 intelligence (AI) technologies that can mine knowledge from vast amounts of data offer  
63 opportunities to disrupt established workflows. In this prospective study, for the first time, we  
64 developed an AI-based Signal-to-Knowledge diagnostic scheme for lung nodule classification  
65 directly from the CT rawdata (the signal). We found that the rawdata achieved almost comparable  
66 performance with CT indicating that we can diagnose diseases without reconstructing images.  
67 Meanwhile, the introduction of rawdata could greatly promote the performance of CT,  
68 demonstrating that rawdata contains some diagnostic information that CT does not have. Our  
69 results break new ground and demonstrate the potential for direct Signal-to-Knowledge domain  
70 analysis.

71

## 72 **Introduction**

73 The discovery of X-rays in 1895 ushered in a new era in the use of imaging for medical diagnostic  
74 purposes. Since then, the non-invasive medical imaging technology subverts the palpation and cut-  
75 and-see scheme [1]. The technological advances in medical imaging have been astounding over  
76 the past 120 years, and modern medical care is increasingly inseparable from imaging technology.  
77 Medical imaging is essential for humans, to allow clinicians to observe from the images and  
78 diagnose diseases. This process can be defined as a path of image-to-knowledge. However,  
79 recently, it is found that the human ability has become a bottleneck in this path hindering the  
80 accurate diagnosis and treatment of diseases [2][3].

81 The emergence of Artificial Intelligence (AI) technology partially solves the problem of the  
82 limited ability of humans in the diagnosis process [4][5][6][7]. AI could automatically mine the  
83 radiographic patterns that related to the occurrence and progression of diseases from the imaging  
84 data, and it has been shown to match and even surpass human abilities in many clinical  
85 applications [8][9][10][11][12]. The essential reason why AI could surpass humans may be that AI  
86 treats images as data rather than the visual image and extracts huge amounts of features for

87 analysis [13][14]. However, the medical image is compressed or filtered data to fit the human eye,  
88 which may be insufficient or imperfect for diagnosis. Take computed tomography (CT) for  
89 example, the CT system first collects rawdata (signal) from the patient, then the reconstruction  
90 method converts rawdata to images (signal-to-image) [15]. Therefore, both AI-based and human-  
91 based diagnosis are processes of signal-to-image-to-knowledge. Medical images suffer from  
92 information distortion in both acquisition and reconstruction processes. The current high sampling  
93 frequency greatly compresses the influence of factors such as motion artifacts in the acquisition  
94 process, so the main reason for the loss of resolution is concentrated in the operations such as  
95 interpolation and sub-optimal statistical weighting in the reconstruction process [16]. Meanwhile,  
96 the unprocessed data size of rawdata is about 10 to 20 times larger than that of CT images (2GB  
97 compare with 180MB). The huge amount of information inside the rawdata is not optimally mined  
98 in current signal-to-image-to-knowledge process, and how to analysis rawdata is of great scientific  
99 interest.

100 Skipping the image process and going directly from signal to knowledge, will hopefully bring  
101 new breakthroughs in disease diagnosis. Inspired by this idea, several previous studies have talked  
102 about the potential value of analysis of rawdata [17][18][19], directly from signal to knowledge.  
103 De Man Q et.al. conducted a simulation experiment to detect and estimate the vessel centerline  
104 from rawdata in the sinogram domain [19]. They achieved encouraging initial results showing the  
105 feasibility of rawdata analysis for clinical CT analysis tasks. We have also reported our simulation  
106 results about lung cancer at American Association for Cancer Research (AACR) conference [20].  
107 However, there is no study about signal-to-knowledge analysis in real clinical tasks of patients.

108 In this prospective study, for the first time, we developed an AI-based signal-to-knowledge  
109 diagnostic scheme for lung nodule classification directly from the CT rawdata (The flowchart was  
110 shown in **Fig. 1**). The value of rawdata alone (Discussion), as well as its added value to CT, are  
111 studied on 276 patients. We found that the rawdata achieved almost comparable performance with  
112 CT indicating that we can diagnose diseases without reconstructed images. Meanwhile, the  
113 introduction of rawdata could greatly promote the performance of CT, demonstrating that rawdata  
114 contains some diagnostic information that CT does not have. This research breaks the routinely  
115 used circle of image-based diagnosis, which may open up a new pathway of signal-to-knowledge  
116 for disease diagnosis.

117

## 118 **Results**

### 119 **Clinical characteristics**

120 The clinical characteristics was summarized in **Table S1**. A total of 276 patients were included and  
121 the number of patients in the training cohort, validation cohort and test cohort were 166, 55 and 55,  
122 respectively. Fifty percent (n = 138) patients were female and the mean of age in the entire dataset  
123 was 58.48 years. Furthermore, there were 21 (8%) small cell carcinoma, 35 (13%) squamous cell  
124 carcinomas and 149 (54%) adenocarcinomas. With respect to lesion location, most patients were  
125 identified as right upper lobe (n = 89, 32%), followed by left lower lobe (n = 67, 24%) and left  
126 upper lobe (n = 64, 23%) in all patients. For lung cancer diagnosis, most patients (n = 225, 82%)  
127 were evaluated as malignancy.

128

### 129 **Performance of CT model and rawdata gain model**

130 This experiment explores the performance improvement that the residual fusion model (Methods)  
131 based on both rawdata and CT images can bring to the model based on CT images only. For  
132 further explore the repeatability and stability of this gain, we tested four different CT models  
133 (Abbreviation for CTM1~CTM4; Methods) and adopted three backbone network architectures for  
134 rawdata feature extraction, namely Densenet121 (DN) [21], Resnet18 (RE) [22] and Resnext18  
135 (RX) [23]. For each CT model (CTM), three rawdata gain models (RGM) based on different  
136 backbone feature extraction networks were constructed. The performance of each RGM was  
137 compared with the original CTM. The receiver operating characteristic curves (ROC) and its area  
138 under the curve (AUC) of four CTMs and the corresponding RGMs based on difference backbone  
139 networks is shown in **Fig. 2**.

140 For each CTM, the residual fusion models based on different backbone networks can obtain  
141 better classification performance on training, validation and test cohorts. For CTM1 model, the  
142 fusion model that produced the maximum performance improvement for the training cohort is  
143 RGM-RX1, and its AUC improvement can reach 0.051 (from 0.757 to 0.808). The fusion model  
144 that produced the maximum performance improvement for the validation cohort is RGM-RE1 and  
145 RGM-RX1, and its AUC improvement can reach 0.033 (from 0.756 to 0.789). The fusion model  
146 that produced the maximum performance improvement for the test cohort is RGM-RE1, and its

147 AUC improvement can reach 0.046 (from 0.807 to 0.853). For CTM2 model, the fusion model  
148 that produced the maximum performance improvement for the training cohort is RGM-RX2, and  
149 its AUC improvement can reach 0.109 (from 0.745 to 0.854). The fusion model that produced the  
150 maximum performance improvement for the validation cohort is RGM-DM2, and its AUC  
151 improvement can reach 0.124 (from 0.698 to 0.822). The fusion model that produced the  
152 maximum performance improvement for the test cohort is RGM-DM2, and its AUC improvement  
153 can reach 0.022 (from 0.760 to 0.782). For CTM3 model, the fusion model that produced the  
154 maximum performance improvement for the training cohort is RGM-RX3, and its AUC  
155 improvement can reach 0.083 (from 0.765 to 0.848). The fusion model that produced the  
156 maximum performance improvement for the validation cohort is RGM-RX3, and its AUC  
157 improvement can reach 0.093 (from 0.760 to 0.853). The fusion model that produced the  
158 maximum performance improvement for the test cohort is RGM-RE3, and its AUC improvement  
159 can reach 0.027 (from 0.773 to 0.800). For CTM4 model, the fusion model that produced the  
160 maximum performance improvement for the training cohort is RGM-RX4, and its AUC  
161 improvement can reach 0.035 (from 0.832 to 0.867). The fusion model that produced the  
162 maximum performance improvement for the validation cohort is RGM-DM4, and its AUC  
163 improvement can reach 0.026 (from 0.756 to 0.782). The fusion model that produced the  
164 maximum performance improvement for the test cohort is RGM-RE4, and its AUC improvement  
165 can reach 0.034 (from 0.833 to 0.867). Overall, using Resnext18 as the backbone network of  
166 rawdata feature extraction can obtain the maximum average performance improvement on the  
167 three cohorts.

168

### 169 **Image feature distribution of the RGMs and gain stability analysis**

170 We performed t-SNE dimensionality reduction on all deep learning features obtained by different  
171 feature extraction networks and counted the true positives, false positives, true negatives and false  
172 negatives of each patient (**Table 1**). Besides, we assigned different colors and markers to visualize  
173 them in the same coordinate system (**Fig. 3**). It can be observed from the **Fig. 3** that the results of  
174 the various RGMs within each CTM are relatively similar, even though they use different feature  
175 extraction networks. **Table 1** also shows the same situation. The gain of the RGMS inside each  
176 CTM is approaching the same trend, such as improving malignant or benign detectable rates.

177 Meanwhile, RGM-RE1, RGM-DN2, RGM-RE2, RGM-DN3, RGM-DN4, RGM-RE4, and RGM-  
178 RX4 could achieve a significant increase in the detectable rate of one category at the expense of a  
179 small number of the other category detectable rates.

180 Therefore, we calculated the optimization rate and error rate of each RGM for the CTM, and  
181 also calculated the proportion of at least 2 model optimizations to all optimization samples, which  
182 can reflect the stability of rawdata's gain. All results were summarized in **Table S2**.

183 The results show that the analysis method incorporating the rawdata has a high optimization  
184 rate for the CTM 1~3 and is greater than the error rate, which is also reflected in the improvement  
185 of AUC. In addition, although different feature extraction networks were used to analysis the  
186 rawdata, the proportion of at least two networks that can be optimized in each CTM is about 80%.  
187 Finally, we found that 7 samples were mispredicted within 4 CTMs. For these 7 samples, the  
188 income of rawdata can correct the prediction results of the 6 CTMs, and the corrected model exists  
189 in each CTM. In summary, the gain of the rawdata for the CTM is very stable.

190

#### 191 **Visual statistics and analysis of the RGMs**

192 To better explain the prediction process of RGM, we visualized the region of most interest in the  
193 RGM by using Gradient-weighted Class Activation Mapping (Grad-CAM). The predictive results  
194 of RGM were most dependent on the information of the RGM-discovered suspicious areas. **Fig. 4**  
195 illustrated the lesion masks and corresponding attention maps from different views of the rawdata.  
196 From **Fig. 4**, we can see that the RGMs can always focus on areas of lesion for prediction  
197 although the input data includes some non-lesion areas. We also calculated the average attention  
198 score of each voxel in lesion and non-lesion in rawdata (Method), and the result showed that the  
199 attention score of the lesion area was 1-2 times as high as the non-lesion area.

200

#### 201 **Stratified analysis of different malignant subgroups**

202 The results of the subgroup analysis for age, sex and lesion size were shown in the **Table S3** and  
203 **Table 2**.

204 In the subgroup with age of  $\leq 60$ , RGM-RX 4 and CTM 4 achieved the similar highest  
205 model performance, with AUC of 0.837 (0.746-0.924) and 0.831 (0.749-0.904), respectively; In

206 the subgroup with age of > 60, RGM-RX 4 achieved the highest model performance with an AUC  
207 of 0.845 (0.713-0.949), which outperformed the best CTM (CTM4 with an AUC of 0.790). In the  
208 male subgroup, CTM4 and RGM-RX 4 performed best, with a similar AUC of 0.804 (0.706-0.882)  
209 and 0.810 (0.707-0.897), respectively; In the female subgroup, RGM-RX 3 achieved the highest  
210 performance with an AUC of 0.885 (0.818-0.945), far exceeding the best CTM (CTM4 with an  
211 AUC of 0.823 (0.720-0.920)). In the subgroup with lesion size  $\leq 23$ mm, RGM-RX 3 achieved the  
212 highest model performance with an AUC of 0.847 (0.781-0.916), far exceeding the best CTM  
213 (CTM4 with an AUC of 0.806); In the subgroup of lesion size >23mm, CTM 4 and RGM-RE 4  
214 showed the similar highest model performance, with AUC of 0.819 (0.719-0.906) and 0.833  
215 (0.703-0.925), respectively. As for the lesion location subgroups, in addition to the similar  
216 performance of CTM 4 and RGM-RX 4 in the subgroup of superior lobe of left lung, RGM  
217 outperformed the CTM, with AUC of 0.840 vs. 0.812 in the subgroup of inferior lobe of left lung,  
218 0.849 vs. 0.807 in the subgroup of superior lobe of right lung, and 0.872 vs. 0.843 in the subgroup  
219 of inferior lobe of right lung.

220

## 221 **Discussion**

222 In this prospective study, for the first time, we validated the potential value of rawdata in real  
223 clinical practice. Interestingly, the rawdata analysis showed comparable performance with CT  
224 images, which indicates that leveraging non-image information holds promise as an alternative to  
225 image-based methods. Moreover, the add value of rawdata to CT images was also confirmed in  
226 this study, which means that the combination of non-image and image data will further promote  
227 the advance of disease diagnosis. This study proposed and validated a feasible method for  
228 diagnosis without image reconstruction, and it has the potential to change existing imaging-based  
229 diagnosis and treatment strategies.

230 The classification of benign and malignant pulmonary nodules is a matter of great clinical  
231 concern[24][25][26]. This study explores the feasibility of rawdata analysis in classifying  
232 indeterminate lung nodules greater than 2 cm in size. The results indicated that rawdata can well  
233 discriminate malignant nodules from benign nodules. Meanwhile, the AUCs of the rawdata in the  
234 training cohort, validation cohort and test cohort are 0.768 (95%CI: 0.681~0.851), 0.760 (95%CI:  
235 0.558~0.922) and 0.782 (95%CI: 0.592~0.924), respectively (**Extended Data Fig. 1**), and there is



236 no statistical difference between the performances of rawdata and CT, which means that the  
237 classification of lung nodules may not need image reconstruction and clinician participation.  
238 Think further, the rawdata model could be applied to the majority of grassroots hospitals, who  
239 have mainstream CT systems but lack technical personnel and clinicians.

240 Our study showed that the introduction of rawdata to CT had an overall improvement over  
241 different CTMs, no matter which backbone network was used. This indicates that rawdata has  
242 unique information which may be lost during the reconstruction processing. Moreover, the  
243 compared with CTM, RGMs showed better stability on the training cohort, validation cohort, and  
244 test cohort. The combination of both non-image and image data could make the model robust. In  
245 addition, we also performed intra-CT and inter-CT analyses. For intra-CTM, fused rawdata  
246 prediction has a higher optimization rate than the error rate which shows a similar gain trend, and  
247 about 80% of the optimized patients appear in at least 2 feature extraction networks. For inter-  
248 CTMs, eighty-five percent of the patients that all CTMs predicted incorrectly have optimizable  
249 RGMs within each CTM. The results also proved that the gain of rawdata is stable across different  
250 convolutional networks and different CTM approaches. Therefore, exploring the drawbacks of  
251 post-reconstructed CT image analysis and developing models for direct diagnosis from rawdata  
252 are the keys to future research. The results of the subgroup analysis showed that the RGMs  
253 performed better than the CTM in most subgroups, especially in the subgroup of older, female,  
254 and smaller lesion size, indicating that the rawdata could provide more valuable information that  
255 brings model gains in subgroups, while this information may have been lost in the process of CT  
256 reconstruction.

257 Our study has some limitations. First, this study involved a small number of patients and the  
258 proportion of positive and negative samples is unbalanced. Further study on large-scale  
259 multicenter datasets should be performed. Second, only patients with single nodule are included in  
260 this study, further validation of our method on patients with multiple nodules should be further  
261 studied. Third, although the rawdata had a comparable performance with CT, it still had a certain  
262 gap with the best CT diagnosis. There is an urgent need to develop novel AI methods specifically  
263 for rawdata.

264 Meanwhile, strong computing power is a problem that cannot be ignored when calculating  
265 rawdata. It is not realistic to read the complete high-frequency scanning data directly to the

266 computing device. Designing appropriate pre -processing algorithms and building deep networks  
267 in combination with characteristics of rawdata are the potential breakthrough points in the future.  
268 Finally, the CT scan scheme is designed for image reconstruction and it may be not suitable for  
269 rawdata analysis. Therefore, novel scan strategies, e.g., scanning for specific diagnostic purposes,  
270 should be developed to maximize the gain of rawdata.

271 In conclusion, for the first time, we validated the potential value of rawdata in real clinical  
272 practice. The rawdata analysis showed comparable performance with CT images, which indicates  
273 that leveraging non-image information holds promise as an alternative to image-based methods.  
274 Moreover, the added value of rawdata to CT images was also confirmed in this study, which  
275 means that the combination of non-image and image will further promote the advance of disease  
276 diagnosis. This study proposed and validated a new feasible direction for diagnosis without image  
277 reconstruction, and it may facilitate the development of fully automated scanning and diagnostic  
278 processes.

279

## 280 **Methods**

### 281 **Patients**

282 In this prospective study, 626 consecutive patients who had a chest CT scan in the First Hospital  
283 of Jilin University from November 2019 to May 2021 were recruited. Eligible patients were  
284 included according to the following inclusion criteria: (i) patients who had a pulmonary lesion  
285 more than 2 cm with contrast enhanced chest CT scan, (ii) rawdata obtained from CT machine  
286 after the imaging examination, (iii) pathological diagnosis of pulmonary lesion with two weeks  
287 interval from CT scan. Patients were excluded on the basis of the following: (i) previous systemic  
288 antineoplastic treatments, (ii) CT images with poor image quality or unreadable scan. After  
289 exclusion, a total of 276 patients were included for modeling experiments.

290 The methods were performed in accordance with Standards for Reporting Diagnostic  
291 accuracy studies (STARD) and approved by the Ethics Committee of the First Hospital of Jilin  
292 University (AF-IRB-032-05).

293

### 294 **Collection of CT image and rawdata**

295 Both the CT images and rawdata were consecutively collected from the First Hospital of Ji Lin

296 University and were acquired with a NeuViz Prime CT system (Neusoft Medical Systems Co.,  
297 Ltd., Shenyang, China). The system parameters of CT scanner included source-to-isocenter  
298 distance of 570 mm, source-to-detector distance of 1040mm, and scanning FOV of 500 mm. The  
299 imaging protocol included contrast-enhanced CT of the chest with variable imaging parameters.  
300 Contrast-enhanced CT scans were performed at a spiral scan mode using 324 mA tube current,  
301 100 kVp tube voltage, 0.5 s rotation time, and 0.9 spiral pitch. CT rawdata were reconstructed using  
302 a kernel F20 at slice thickness of 1.0 mm with image pixel range from 0.59 mm to 0.98 mm and  
303 image matrix of 512 by 512. In addition, we also acquired the initial height and initial view angle  
304 of the CT detector each time the patient underwent a scan. Finally, CT images and rawdata from  
305 each scanner were randomly stratified into one of three cohorts in a 6:2:2 ratio: a training cohort, a  
306 validation cohort and a test cohort. All in all, **Table S4** describes CT scanner information, system  
307 parameters and imaging parameters.

308

### 309 **lesion segmentations in CT images**

310 The segmentations of primary lesion were manually delineated across all the sections in the axial  
311 view using annotation tool in ISD (IntelliSpace Discovery, Philips, German). The regions of  
312 interest were annotated and reviewed by four radiologists with 8 to 25 years' chest CT experience.  
313 All radiologists were blinded to any clinical or histopathologic information. The annotation was  
314 labeled as five common categories according lesions' pulmonary lobe.

315

### 316 **Realization of typical CT models**

317 There are many studies on benign-malignant lung nodule classification on chest CT. We selected  
318 four typical papers from the major journals, including *IEEE Transactions on medical imaging*,  
319 *Medical image analysis*, and *Nature medicine*, which refer to multi-scale ensemble method  
320 (CTM1) [27], global and local information fusion method (CTM2) [26], loss function-based  
321 method (CTM3) [28], and multi-view fusion (CTM4) method [29]. We further performed  
322 experiments on four typical models with our dataset, and all the realization details are described in

323 **Supplementary 1.**

324

### 325 **Extraction of lesion region from raw data**

326 After acquiring 4 CTMs, we proceeded to perform rawdata gain experiments. The first step of the  
327 experiment is to select projection surface containing lesions in the rawdata. The rawdata of CT  
328 scans contains three dimensions: 1) the index dimension representing the acquisition order; 2) the  
329 projection surface which is the detector receives the x-ray attenuation, where the channel and row  
330 directions are defined as x and y, respectively. All lesion segmentation regions of rawdata were  
331 derived from the binarized segmentation of CT image after being represented in a unified  
332 coordinate system. The complete derivation can be condensed into three steps: orientation,  
333 querying and mapping.

334 1) Orientation.

335 On the derivation of localization, we took the segmented regions in the CT image as the  
336 research object, and the localization calculation mainly includes cross-sectional localization and  
337 height localization. For cross-sectional positioning, we set the center point between the CT source  
338 and detector as the coordinate origin (which is also the rotation center of the CT gantry), parallel  
339 to the cross-section of the CT image. Next, the motion trajectory can be characterized by the scan  
340 index  $t$ , the rotation radius  $r$  and the angle  $\theta$ . In order to obtain the above parameters, we first  
341 read the origin coordinates ( $x_{\text{origin}}$ ,  $y_{\text{origin}}$  and  $z_{\text{origin}}$ ), and the offset values ( $x_{\text{offset}}$  and  $y_{\text{offset}}$ )  
342 can be calculated through voxel spacing and image size ( $x_{\text{size}}$  and  $y_{\text{size}}$ ).

$$343 \quad x_{\text{offset}} = x_{\text{origin}} + x_{\text{spacing}} \times \frac{1}{2} x_{\text{size}}$$

$$344 \quad y_{\text{offset}} = y_{\text{origin}} + y_{\text{spacing}} \times \frac{1}{2} y_{\text{size}}$$

345 Next, with the help of the offset values and the voxel coordinates  $x_{\text{CT}}$  and  $y_{\text{CT}}$  in the CT  
346 image, the distance from the coordinate origin ( $x_{\text{length}}$  and  $y_{\text{length}}$ ) can be calculated as:

$$347 \quad x_{\text{length}} = x_{\text{spacing}} \times \left( x_{\text{CT}} - \frac{1}{2} x_{\text{size}} \right) - x_{\text{offset}}$$

$$348 \quad y_{\text{length}} = y_{\text{spacing}} \times \left( y_{\text{CT}} - \frac{1}{2} y_{\text{size}} \right) - y_{\text{offset}}$$

349 Otherwise, the radius  $r$ , and the starting angle  $\theta_0$  can be obtained.

350 
$$r = \sqrt{x^2 + y^2}$$

351 
$$\theta_0 = \arctan \frac{y_{\text{length}}}{x_{\text{length}}}$$

352 Meanwhile, by introducing the scanning period of the machine, we got the angle change  $\Delta\theta$   
353 with the following relationship:

354 
$$y_{\text{length}} = r \times \cos(\Delta\theta \cdot t + \theta_0)$$

355 
$$x_{\text{length}} = r \times \sin(\Delta\theta \cdot t + \theta_0)$$

356 For height positioning, we directly obtained the initial height  $h_{\text{start}}$  of the voxel through the  
357 coordinate  $z$ , slice thickness and origin of the voxel point in CT images.

358 2) Querying.

359 Our purpose in this step is to determine the interval of index dimension  $t$  in which tumor  
360 voxel appears in the raw data. Since there is a cone beam in the projection, we first calculated the  
361 change function  $h_{\text{area}}$  of the voxel, where  $d$  is the distance from the voxel to the X-ray focal spot  
362 on the x-axis;  $l$  is the distance from the focal spot to the detector. The number of detector rows is  
363  $n_y$ ; the channel spacing along y-axis is  $\Delta n_y$ .

364 
$$d = \frac{1}{2}l + x_{\text{length}}$$

365 
$$h_{\text{area}} = \frac{1}{l} \left( \frac{1}{2} n_y \times \Delta n_y \times d \right)$$

366 Next, we determined the index ( $t$ ) range of the voxel in the rawdata by the following  
367 inequality, where  $h_0$  is the initial height at which the detector start to scan;  $\Delta h$  is the height  
368 change in a scan.

369 
$$h_0 - \Delta h \cdot t \leq h_{\text{start}} + h_{\text{area}}$$

370 
$$h_0 - \Delta h \cdot t \geq h_{\text{start}} - h_{\text{area}}$$

371 To reduce computational complexity, we first extracted the highest and lowest masks in the  
372 segmentation images, and calculated the start and end indices of two voxels. Then, we initially  
373 located the range of index dimensions. Within this interval, we computed the mapping result of

374 voxels within the layer.

375 3) Mapping.

376 Through the above calculation, we have obtained the index interval corresponding to the  
377 voxel, then the voxel appearing in index is obtained by calculating the projection data of the index  
378 layer by layer. The coordinates of each voxel on the projection surface are defined as  $x_{\text{raw}}$  and  
379  $y_{\text{raw}}$ , respectively.  $y_{\text{raw}}$  is related to the height  $h_t$ ,  $h_{\text{area}}$  at the  $t$  index and the number of detector  
380 rows  $n_y$  in the detector, so we determined its height difference relative to the detector by the  
381 following formula, and then calculated its coordinates in the projection.

$$382 \quad y_{\text{voxel}} = \frac{h_t}{h_{\text{area}}} \cdot \frac{(n_y - 1)}{2}$$

383 Since the x-axis of the projection plane is equiangularly sampled,  $x_{\text{raw}}$  can be acquired  
384 through the angle at the  $t$  index  $\theta_t$ , the view angle  $\theta_d$  of the detector, and the number of channels  
385 in the detector  $n_x$ .

$$386 \quad x_{\text{voxel}} = \frac{2\theta_t}{\theta_d} \cdot \frac{(n_x - 1)}{2}$$

387 After obtaining the segmentation files of lesions in the raw data, we saved the raw data  
388 segment through the initial index interval, and used this as the training data for this gain  
389 experiment. It should be added that there are different directions in the actual retrieval of raw data  
390 (From head to foot or foot to head). We used the same spatial relationship to modify the inequality  
391 for different directions and then located the lesion.

392

### 393 **Construction of RGM based on CT images**

394 To explore whether the rawdata contained unique information, we built residual fusion models  
395 through the rawdata and fused it with CTMs' output to determine whether the rawdata could bring  
396 benefits. First, we built three feature extraction networks using the rawdata. Based on the memory  
397 need of calculation, we sampled the index dimension of rawdata fragments containing lesions to  
398 one-eighth, and the same size was resampling based on the average value by equal interval  
399 sampling. For the Channel dimension, we directly removed the data outside the reconstruction

400 area from both sides, and resampling with the row dimension into half of the size. For model  
401 building, we did not modify Densenet121 [21], Resnet18 [22] and Resnext18 [23] in 3D with the  
402 purpose of directing the direct gain of nude data as much as possible. The training settings and  
403 parameters are detailed in **Supplementary 2**.

404 The core of the residual fusion model is to obtain the correction of the CT model output, and  
405 the origin of the idea is that the learning residual is easier which is mentioned in Resnet. The  
406 probabilities of predicting the patients as positive by the CTMs were fused with the predicted  
407 probabilities of the rawdata models. This fusion is performed during the training process.  
408 Specifically, the probability of predicting one patient as positive was calculated as:

$$409 \quad Output_{\text{positive}} = Raw_{\text{positive}} + CT_{\text{positive}}$$

410 The probability of predicting one patient as negative was calculated as:

$$411 \quad Output_{\text{negative}} = Raw_{\text{negative}} + (1 - CT_{\text{positive}})$$

412 After the output fusion of the CTM and rawdata model, the loss function was used to  
413 calculate the loss and optimize the model. The three feature extraction networks built with rawdata  
414 were fused with the four representative CTMs described above to obtain four raw gain models  
415 respectively, which were: raw gain model-Densenet121 (RGM-DN 1/2/3/4), raw gain model-  
416 Resnet18 (RGM-RE 1/2/3/4), raw gain model-Resnext18 (RGM-RX 1/2/3/4). Therefore, we  
417 obtain 12 raw gain models. Then the RGMs were compared with the CTMs to evaluate the  
418 benefits of the rawdata.

419

#### 420 **The calculation of the average attention score**

421 For calculating the average attention score of each voxel, we first used the segmentation data of  
422 lesion in rawdata to obtain non-lesion area by unary complement. Next, we dotted and summed  
423 the segmentation data of lesion and non-lesion areas with the attention matrix. Finally, the average  
424 attention score was obtained by dividing the total amount of attention in the two areas by the  
425 number of voxels in the segmented regions, respectively. It should be noted that we also  
426 normalized the average attention score of the lesion area and the non-lesion area in each rawdata,  
427 so as to obtain a more intuitive comparison result.

428

## 429 **Data availability**

430 The image features and output values associated with the CTMs and the RGMs are stored on  
431 GitHub ([https://github.com/CASIAMI/rawdata\\_gain](https://github.com/CASIAMI/rawdata_gain)). The original data that support the findings  
432 of this study are available from the corresponding author upon reasonable request.

433

## 434 **Code availability**

435 Source code for related CT and raw data methods can be found from GitHub  
436 ([https://github.com/CASIAMI/rawdata\\_gain](https://github.com/CASIAMI/rawdata_gain)).

437

## 438 **References**

- 439 [1] Ciccarelli, E., Jacobs, A. & Berman, P. Looking back on the millennium in medicine. *N Engl*  
440 *J Med* **342**, 42-49 (2000).
- 441 [2] Lauwerends, L.J., *et al.* Real-time fluorescence imaging in intraoperative decision making for  
442 cancer surgery. *The Lancet Oncology* **22**, e186-e195 (2021).
- 443 [3] Lehman, C.D., *et al.* Diagnostic accuracy of digital screening mammography with and  
444 without computer-aided detection. *JAMA internal medicine* **175**, 1828-1837 (2015).
- 445 [4] Bi, W.L., *et al.* Artificial intelligence in cancer imaging: clinical challenges and applications.  
446 *CA: a cancer journal for clinicians* **69**, 127-157 (2019).
- 447 [5] Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L.H. & Aerts, H.J. Artificial intelligence  
448 in radiology. *Nature Reviews Cancer* **18**, 500-510 (2018).
- 449 [6] Litjens, G., *et al.* A survey on deep learning in medical image analysis. *Medical image*  
450 *analysis* **42**, 60-88 (2017).
- 451 [7] Lambin, P., *et al.* Radiomics: the bridge between medical imaging and personalized medicine.  
452 *Nature reviews Clinical oncology* **14**, 749-762 (2017).
- 453 [8] Liu, X., *et al.* A comparison of deep learning performance against health-care professionals in  
454 detecting diseases from medical imaging: a systematic review and meta-analysis. *The lancet*  
455 *digital health* **1**, e271-e297 (2019).
- 456 [9] Killock, D. AI outperforms radiologists in mammographic screening. *Nature Reviews*  
457 *Clinical Oncology* **17**, 134-134 (2020).
- 458 [10] Cruz Rivera, S., Liu, X., Chan, A.-W., Denniston, A.K. & Calvert, M.J. Guidelines for  
459 clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI  
460 extension. *Nature medicine* **26**, 1351-1363 (2020).
- 461 [11] Dong, D., *et al.* Deep learning radiomic nomogram can predict the number of lymph node  
462 metastasis in locally advanced gastric cancer: an international multicenter study. *Annals of*  
463 *Oncology* **31**, 912-920 (2020).
- 464 [12] Huang, Y.-q., *et al.* Development and validation of a radiomics nomogram for preoperative  
465 prediction of lymph node metastasis in colorectal cancer. *Journal of clinical oncology* **34**,  
466 2157-2164 (2016).
- 467 [13] Mu, W., Schabath, M.B. & Gillies, R.J. Images Are Data: Challenges and Opportunities in



- 468 the Clinical Translation of Radiomics. *Cancer Research* **82**, 2066-2068 (2022).
- 469 [14] Gillies, R.J., Kinahan, P.E. & Hricak, H. Radiomics: images are more than pictures, they are  
470 data. *Radiology* **278**, 563 (2016).
- 471 [15] Zhu, B., Liu, J.Z., Cauley, S.F., Rosen, B.R. & Rosen, M.S. Image reconstruction by domain-  
472 transform manifold learning. *Nature* **555**, 487-492 (2018).
- 473 [16] Wang, G., Ye, J.C. & De Man, B. Deep learning for tomographic image reconstruction.  
474 *Nature Machine Intelligence* **2**, 737-748 (2020).
- 475 [17] Kalra, M., Wang, G. & Orton, C.G. Radiomics in lung cancer: Its time is here. *Medical*  
476 *physics* **45**, 997-1000 (2018).
- 477 [18] Wang, G., Ye, J.C., Mueller, K. & Fessler, J.A. Image reconstruction is a new frontier of  
478 machine learning. *IEEE transactions on medical imaging* **37**, 1289-1296 (2018).
- 479 [19] De Man, Q., *et al.* A two-dimensional feasibility study of deep learning-based feature  
480 detection and characterization directly from CT sinograms. *Medical physics* **46**, e790-e800  
481 (2019).
- 482 [20] Dong, D., *et al.* Abstract CT274: Diagnosis based on signal: The first time break the routinely  
483 used circle of signal-to-image-to-diagnose. *Cancer Research* **80**, CT274-CT274 (2020).
- 484 [21] Huang, G., Liu, Z., Van Der Maaten, L. & Weinberger, K.Q. Densely connected  
485 convolutional networks. in *Proceedings of the IEEE conference on computer vision and*  
486 *pattern recognition* 4700-4708 (2017).
- 487 [22] He, K., Zhang, X., Ren, S. & Sun, J. Deep residual learning for image recognition. in  
488 *Proceedings of the IEEE conference on computer vision and pattern recognition* 770-778  
489 (2016).
- 490 [23] Xie, S., Girshick, R., Dollár, P., Tu, Z. & He, K. Aggregated residual transformations for deep  
491 neural networks. in *Proceedings of the IEEE conference on computer vision and pattern*  
492 *recognition* 1492-1500 (2017).
- 493 [24] Shen, W., *et al.* Multi-crop convolutional neural networks for lung nodule malignancy  
494 suspiciousness classification. *Pattern Recognition* **61**, 663-673 (2017).
- 495 [25] Mukherjee, P., *et al.* A shallow convolutional neural network predicts prognosis of lung  
496 cancer patients in multi-institutional computed tomography image datasets. *Nature machine*  
497 *intelligence* **2**, 274-282 (2020).
- 498 [26] Ardila, D., *et al.* End-to-end lung cancer screening with three-dimensional deep learning on  
499 low-dose chest computed tomography. *Nature medicine* **25**, 954-961 (2019).
- 500 [27] Xu, X., *et al.* MSCS-DeepLN: Evaluating lung nodule malignancy using multi-scale cost-  
501 sensitive neural networks. *Medical Image Analysis* **65**, 101772 (2020).
- 502 [28] Liu, L., Dou, Q., Chen, H., Qin, J. & Heng, P.-A. Multi-task deep model with margin ranking  
503 loss for lung nodule analysis. *IEEE transactions on medical imaging* **39**, 718-728 (2019).
- 504 [29] Xie, Y., *et al.* Knowledge-based collaborative deep learning for benign-malignant lung  
505 nodule classification on chest CT. *IEEE transactions on medical imaging* **38**, 991-1004  
506 (2018).
- 507 [30] Chen, S., Ma, K. & Zheng, Y. Med3d: Transfer learning for 3d medical image analysis. *arXiv*  
508 *preprint arXiv:1904.00625* (2019).
- 509

## 510 **Acknowledgements**

511 This work was supported by the National Key R&D Program of China (2017YFA0205200),  
512 National Natural Science Foundation of China (82022036, 91959130, 81971776, 62027901,  
513 81930053, 81771924), the Beijing Natural Science Foundation (Z20J00105), Strategic Priority  
514 Research Program of Chinese Academy of Sciences (XDB38040200), Chinese Academy of  
515 Sciences under Grant No. GJJSTD20170004 and QYZDJ-SSW-JSC005, the Project of High-  
516 Level Talents Team Introduction in Zhuhai City (Zhuhai HLHPTP201703), the Youth Innovation  
517 Promotion Association CAS (Y2021049) and the China Postdoctoral Science Foundation  
518 (2021M700341). The authors would like to acknowledge the instrumental and technical support of  
519 Multi-modal biomedical imaging experimental platform, Institute of Automation, Chinese  
520 Academy of Sciences.

521

## 522 **Author contributions**

523 B.X.H., Y.B.Z., C.X.S., T.T., K.S. and H.L.L. developed the network architecture and  
524 data/modeling infrastructure, training and testing setup. B.X.H., Y.B.Z., C.X.S., T.T., K.S. and  
525 H.L.L. wrote the methods. B.X.H., C.X.S. and T.T. created the figures. B.X.H. and M.J.F.  
526 performed statistical analysis. J.T., D.D., Z.Y.L., K.W., Z.Q.W., W.M., S.W., Z.C.T., S.T.Z.,  
527 J.W.W. and L.Z.S. advised on the modeling techniques. L.X.T., L.W.W., S.P.Z. and J.T.L.  
528 provided raw data structure information. D.D., B.X.H., Y.B.Z., C.X.S., T.T., K.S. H.L.L., L.W.W.  
529 and Y.G. wrote the manuscript. H.M.Z., Y.G., M.W., F.Y.M., L.D., L.L.Z. and S.W. provided  
530 clinical expertise and guidance on the study design. H.M.Z., Y.G., M.W., F.Y.M. and L.D. created  
531 the clinical datasets, interpreted the data and defined the clinical labels. L.X.T., W.L.W., and F.H.  
532 created the rawdata sets. J.T., D.D., F.H. and H.M.Z. initiated the project and provided guidance  
533 on the concept and design. J.T., F.H. and H.M.Z. supervised the project.


534

## 535 **Competing interests**

536 The authors declare that they have no competing interests.

537

538 **Figures and Tables**




539

540

541

**Figure 1. Flow chart of rawdata gain experiment.**



542


543

544


545

546

**Figure 2. CT model and raw data gain results.** (A) shows the ROC curves of each CTM and residual fusion model based on different backbone feature extraction networks; (B) Bar graph of reaction AUC gain. DM, Densenet121; RE, Resnet18, RX, Renext18.



**Figure 3. Feature distribution of the RGMs and the heatmap of prediction results. (A) shows the feature distribution in the RGM, and different marks and colors reflect different authenticity and prediction categories. (B) shows the prediction results of all real categories, CTMs and RGMs.**




552

553

554

Figure 4. Lesion trajectory in rawdata and the Grad-Cam graphs of the RGMs.



555  
556  
557

**Extended Data Fig. 1. The ROC curve of the model built by rawdata only.**



558

**Table 1** Detailed result statistics of raw data for CT models

<b>Model</b>	<b>True positive proportion</b>	<b>False negative proportion</b>	<b>False positive proportion</b>	<b>True negative proportion</b>	<b>True positive rate</b>	<b>True negative rate</b>
CTM1	0.616	0.199	0.069	0.116	0.756	0.627
RGM-DN1	0.699	0.116	0.091	0.094	0.858	0.508
RGM-RE1	0.543	0.272	0.043	0.141	0.666	0.766
RGM-RX1	0.761	0.054	0.120	0.065	0.934	0.351
CTM2	0.678	0.138	0.101	0.083	0.831	0.451
RGM-DN2	0.656	0.159	0.076	0.109	0.805	0.589
RGM-RE2	0.594	0.221	0.051	0.134	0.729	0.724
RGM-RX2	0.605	0.210	0.058	0.127	0.742	0.686
CTM3	0.460	0.355	0.022	0.163	0.564	0.881
RGM-DN3	0.529	0.286	0.025	0.159	0.649	0.864
RGM-RE3	0.656	0.159	0.072	0.112	0.805	0.609
RGM-RX3	0.685	0.130	0.080	0.105	0.840	0.568
CTM4	0.634	0.181	0.043	0.141	0.778	0.766
RGM-DN4	0.652	0.163	0.047	0.138	0.800	0.746
RGM-RE4	0.681	0.134	0.051	0.134	0.836	0.724
RGM-RX4	0.696	0.120	0.043	0.141	0.853	0.766

559



Table 2. The performance of 12 raw gain models in subgroup analysis. S

AUC 95%CI		RGM- DN 1	RGM- RE 1	RGM- RX 1	RGM- DN 2	RGM- RE 2	RGM- RX 2	RGM- DN 3	RGM- RE 3	RGM- RX 3	RGM- DN 4	RGM- RE 4	RGM- RX 4
Age	<=60	0.731 (0.647- 0.825)	0.760 (0.667- 0.844)	0.756 (0.667- 0.837)	0.764 (0.668- 0.845)	0.790 (0.709- 0.874)	0.786 (0.705- 0.867)	0.800 (0.719- 0.870)	0.825 (0.743- 0.895)	0.824 (0.750- 0.894)	0.829 (0.749- 0.903)	0.836 (0.746- 0.915)	<b>0.837</b> <b>(0.746- 0.924)</b>
	>60	0.801 (0.680- 0.908)	0.781 (0.664- 0.894)	0.804 (0.700- 0.900)	0.740 (0.610- 0.859)	0.792 (0.678- 0.901)	0.815 (0.699- 0.932)	0.744 (0.636- 0.833)	0.767 (0.648- 0.863)	0.799 (0.673- 0.914)	0.808 (0.661- 0.926)	0.835 (0.690- 0.945)	<b>0.845</b> <b>(0.713- 0.949)</b>
Sex	Male	0.693 (0.584- 0.794)	0.698 (0.591- 0.793)	0.697 (0.601- 0.792)	0.737 (0.626- 0.826)	0.725 (0.608- 0.837)	0.714 (0.600- 0.824)	0.702 (0.605- 0.791)	0.736 (0.634- 0.834)	0.717 (0.617- 0.822)	0.793 (0.695- 0.877)	0.791 (0.686- 0.889)	<b>0.810</b> <b>(0.707- 0.897)</b>
	Female	0.808 (0.716- 0.898)	0.825 (0.728- 0.901)	0.835 (0.749- 0.901)	0.786 (0.695- 0.871)	0.842 (0.749- 0.916)	0.859 (0.777- 0.927)	0.852 (0.780- 0.921)	0.863 (0.784- 0.920)	<b>0.885</b> <b>(0.818- 0.945)</b>	0.849 (0.741- 0.944)	0.873 (0.764- 0.958)	0.863 (0.739- 0.954)
Tumor Size	<=23mm	0.771 (0.677- 0.849)	0.786 (0.689- 0.869)	0.815 (0.732- 0.893)	0.775 (0.685- 0.863)	0.821 (0.743- 0.894)	0.828 (0.752- 0.901)	0.800 (0.722- 0.869)	0.823 (0.736- 0.888)	<b>0.847</b> <b>(0.781- 0.916)</b>	0.821 (0.729- 0.906)	0.836 (0.744- 0.925)	0.839 (0.731- 0.926)
	>23mm	0.737 (0.603- 0.847)	0.746 (0.627- 0.854)	0.709 (0.582- 0.815)	0.748 (0.639- 0.847)	0.753 (0.634- 0.864)	0.754 (0.641- 0.859)	0.759 (0.657- 0.850)	0.782 (0.684- 0.874)	0.775 (0.666- 0.868)	0.822 (0.712- 0.924)	<b>0.833</b> <b>(0.703- 0.925)</b>	0.831 (0.729- 0.928)

<b>Tumor Location</b>	<b>superior left</b>	0.679 (0.520- 0.836)	0.667 (0.464- 0.836)	0.743 (0.616- 0.881)	0.638 (0.469- 0.812)	0.683 (0.480- 0.847)	0.737 (0.517- 0.899)	0.824 (0.702- 0.925)	0.812 (0.701- 0.916)	0.810 (0.680- 0.914)	0.861 (0.754- 0.953)	0.885 (0.773- 0.964)	<b>0.909</b> <b>(0.829- 0.979)</b>
	<b>inferior left</b>	0.796 (0.638- 0.915)	0.789 (0.652- 0.921)	0.769 (0.600- 0.896)	0.741 (0.584- 0.881)	0.759 (0.607- 0.905)	0.771 (0.599- 0.911)	0.775 (0.633- 0.894)	0.793 (0.656- 0.907)	0.812 (0.650- 0.934)	0.813 (0.651- 0.953)	<b>0.840</b> <b>(0.688- 0.969)</b>	0.833 (0.661- 0.961)
	<b>superior right</b>	0.739 (0.618- 0.855)	0.814 (0.698- 0.912)	0.785 (0.673- 0.876)	0.810 (0.704- 0.900)	0.843 (0.740- 0.930)	0.811 (0.685- 0.901)	0.756 (0.633- 0.864)	0.802 (0.675- 0.909)	0.815 (0.675- 0.899)	0.843 (0.730- 0.936)	0.848 (0.741- 0.934)	<b>0.849</b> <b>(0.729- 0.939)</b>
	<b>Inferior right</b>	0.821 (0.638- 0.957)	0.809 (0.655- 0.957)	0.795 (0.617- 0.937)	<b>0.872</b> <b>(0.744- 0.970)</b>	0.849 (0.701- 0.970)	0.849 (0.700- 0.970)	0.786 (0.617- 0.923)	0.835 (0.705- 0.961)	0.812 (0.616- 0.959)	0.721 (0.430- 0.942)	0.764 (0.470- 0.981)	0.775 (0.524- 0.962)

562

**Table S1.** Clinical characteristic statistics

<b>Characteristics</b>	<b>Training cohort (N=166)</b>	<b>Validation cohort (N=55)</b>	<b>P value *</b>	<b>Test cohort (N=55)</b>	<b>P value **</b>
Age	58.80 ± 10.16	58.48 ± 10.07	0.06	59.38 ± 8.25	0.06
Sex			0.17		0.84
	Female	80 (0.48)	33 (0.60)	25 (0.45)	
	Male	86 (0.52)	22 (0.40)	30 (0.55)	
Tumor height	28.29 ± 17.22	27.76 ± 16.91	0.20	27.35 ± 14.50	0.20
Pathology subtype			0.90		0.26
	Adenocarcinoma	84 (0.71)	26 (0.67)	39 (0.83)	
	Squamous carcinoma	22 (0.18)	8 (0.21)	5 (0.11)	
	Small cell carcinoma	13 (0.11)	5 (0.13)	3 (0.06)	
Left upper Lobe			0.15		0.25
	No	121 (0.73)	46 (0.84)	45 (0.82)	
	Yes	45 (0.27)	9 (0.16)	10 (0.18)	
Left lower Lobe			0.88		0.54
	No	124 (0.75)	41 (0.75)	44 (0.80)	
	Yes	42 (0.25)	14 (0.25)	11 (0.20)	
Right upper Lobe			0.88		0.04
	No	118 (0.71)	39 (0.71)	30 (0.55)	
	Yes	48 (0.29)	16 (0.29)	25 (0.45)	
Right middle lobe			0.56		0.53
	No	154 (0.93)	49 (0.89)	53 (0.96)	
	Yes	12 (0.07)	6 (0.11)	2 (0.04)	
Right lower Lobe			0.83		0.77
	No	137 (0.83)	44 (0.80)	47 (0.85)	
	Yes	29 (0.17)	11 (0.20)	8 (0.15)	
Category			0.91		0.91
	Malignancy	135 (0.81)	45 (0.82)	45 (0.82)	
	Benign	31 (0.19)	10 (0.18)	10 (0.18)	

Noted that other categories of malignant tumors were not included in the statistics as sparse categories. \* The p Value is the test result of the training cohort and the validation cohort; \*\* the p Value is the test result of the training cohort and the test cohort.

563

564

**Table S2** Detailed gain statistics of raw data for CT models

ID of CT model	Optimization rate of error sample	Error rate of correct sample	Ratio of at least 2 gain model optimizations
CTM1	0.771 (81/105)	0.329 (57/173)	0.827 (67/81)
CTM2	0.676 (46/68)	0.286 (60/210)	0.848 (39/46)
CTM3	0.724 (76/105)	0.208 (36/173)	0.789 (60/76)
CTM4	0.406 (26/64)	0.079 (17/214)	0.846 (22/26)

565

566

**Table S3.** The performance of four CT models in subgroup analysis.

AUC 95%CI		CTM 1	CTM 2	CTM 3	CTM 4
Age	≤60	0.790 (0.707-0.861)	0.739 (0.626-0.831)	0.801 (0.729-0.866)	<b>0.831</b> <b>(0.749-0.904)</b>
	>60	0.705 (0.546-0.823)	0.725 (0.592-0.849)	0.701 (0.599-0.799)	<b>0.790</b> <b>(0.672-0.899)</b>
Sex	Male	0.765 (0.680-0.848)	0.748 (0.641-0.866)	0.721 (0.626-0.803)	<b>0.804</b> <b>(0.706-0.882)</b>
	Female	0.752 (0.638-0.858)	0.729 (0.626-0.827)	0.803 (0.703-0.888)	<b>0.823</b> <b>(0.720-0.920)</b>
Tumor Size	≤23mm	0.760 (0.647-0.843)	0.696 (0.569-0.809)	0.753 (0.664-0.833)	<b>0.806</b> <b>(0.699-0.888)</b>
	>23mm	0.764 (0.670-0.852)	0.798 (0.697-0.890)	0.774 (0.684-0.862)	<b>0.819</b> <b>(0.719-0.906)</b>
Tumor Location	superior left	0.802 (0.671-0.901)	0.671 (0.463-0.880)	0.873 (0.749-0.961)	<b>0.921</b> <b>(0.843-0.980)</b>
	inferior left	0.698 (0.526-0.852)	0.732 (0.557-0.868)	0.698 (0.562-0.840)	<b>0.812</b> <b>(0.675-0.934)</b>
	superior right	0.759 (0.615-0.878)	0.732 (0.578-0.852)	0.731 (0.603-0.844)	<b>0.807</b> <b>(0.683-0.912)</b>
	Inferior right	0.781 (0.630-0.906)	<b>0.843</b> <b>(0.712-0.950)</b>	0.769 (0.617-0.901)	0.695 (0.443-0.928)

567

568 **Table S4.** Scanner information, system parameters and imaging parameters for the Chest CT  
569 examinations

<b>Manufacturer</b>	<b>Scanner</b>	<b>System parameters</b>	<b>Contrast-enhanced CT imaging parameters</b>
Neusoft Medical Systems Co., Ltd., Shenyang, China	NeuViz Prime	Source-to-detector distance, 1040 mm; Source-to-isocenter distance, 570 mm; Scanning FOV, 500 mm; Scanning frequency, 2320 times/round; Detector channel, 672 pcs; Detector row, 64 pcs; Detector channel spacing, 0.625 mm.	Tube current, 324mA; Tube voltage, 100kV; Rotation time, 0.5 s; Spiral pitch, 0.9; Image matrix, 512x512; Pixel spacing, 0.59~0.94 mm Slice thickness, 1mm; Kernel, F20; Image time relative to onset of contrast material injection, pre-contrast 60s~70s.

570

## 571 **Supplement 1. Implementation and optimization details of typical CT models**

572

573 Considering the differences in experimental design between our study and the typical models, we  
574 need to make appropriate modifications to make the typical models have the best performances on  
575 our dataset. The difference is mainly reflected in data volume and data imbalance. The amount of  
576 data in previous articles ranged from 1018 to more than 20,000, much larger than that in this  
577 experiment (276). Therefore, we applied small data learning related techniques (including pre-  
578 trained model and sharing network weight) for four typical CT models. Hence, in our study, a pre-  
579 trained 3D-resnet18 was used for 3D input, which was pre-trained using eight medical datasets  
580 [30], a pre-trained 2D-resnet50 was used for 2D input. To train the subnets effectively using our  
581 small dataset, only the last layer (layer 4) and full connected network were trained in this study. In  
582 addition, for data imbalance, we used resampling strategy during training.

583 Specific to each of these models, we describe them in detail below. CTM1 was a multi-scale  
584 ensemble model, which ensembled three subnets whose networks were all the same, except for the  
585 input size. The input data were cropped from CT images using three different sizes,  $32 \times 32 \times 32$ ,  
586  $48 \times 48 \times 48$ , and  $64 \times 64 \times 64$  pixels. The outputs of three subnets were weighted to obtain the final  
587 ensemble results, and a grid search was used to tune the weight values. In addition, AUC loss  
588 proposed in original paper was used for dealing with data imbalance. CTM2 combined the  
589 features of both the entire CT volume and the region of interest cropped from CT volume, so that  
590 all predictions relied on both nodule-level local information and global context from the entire CT  
591 volume. In addition, CTM2 was trained with focal loss to mitigate the data imbalance. CTM3  
592 designed a deep network with a margin ranking loss to enhance the discrimination capability on  
593 ambiguous nodule cases. In our study, 3D input was used to preserve the spatial information of  
594 pulmonary nodule. CTM4 was a multi-view deep network, which ensembled the outputs of nine  
595 2D-view subnets to characterize the 3D nodule. Each subnet combined three types of image  
596 patches, and each patch was input into a pre-trained ResNet-50 network. In this study, all networks  
597 shared weights. Finally, nine subnets were used jointly to classify nodules with an average  
598 weighting scheme. For model training, the batch size was set as 32. The cross-entropy loss was  
599 used as the loss function, and the SGD optimizer was applied. The start learning rates were set as  
600 0.001, and the models were trained for 100 epochs.

## Supplement 2. Model training and statistical analysis methods

601

602

603 For model building, the batch size was set as 64. The Cross-Entropy loss was used as the loss  
604 function, and the Adam optimizer was applied. The start learning rates were set as  $1 \times 10^{-5}$ ,  $1 \times$   
605  $10^{-6}$  separately, and the learning rate decay was set as 0.001. Meanwhile, we also added weight  
606 attenuation. The weight decay was set as 0.01, 0.05, and 0.1 separately. The model was trained for  
607 50 epoches and select the best parameters with the lowest loss of validation cohort. The three  
608 RGMs built based on the three structures were all trained with the above setting.

609 For statistical analysis, discrete variables and continuous variables are calculated in the chi-  
610 squared test and Man-Whitney U test, respectively. All models are implemented in Python 3.7.3  
611 (<https://www.python.org/>) with Numpy (version  $\geq 1.16.4$ ), SciPy (version  $\geq 1.3.0$ ), Matplotlib  
612 (version  $\geq 3.1.1$ ), Scikit-Learn (version  $\geq 1.10.1$ ), Statsmodels (version  $\geq 0.12.2$ ) and Pandas  
613 (version  $\geq 0.25.0$ ). All models were trained in python package named Pytorch (version  $\geq 1.10.1$ ;  
614 <https://pytorch.org/>) with 4 Graphics Processing Units of NVIDIA TITAN RTX (24G).